Here’s whether Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bullish.
🟢
Bullish
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+6.58% over 10 days); RSI 50 — healthy momentum range; strong 1-year return of +93.3%; 3-month momentum positive (+52.1%). Currently 5.8% off its 52-week high. Score: +7/7.
AMRX is in a confirmed uptrend, trading above both its 50-day ($17.12) and 200-day ($13.87) moving averages. An RSI of 50.5 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +93.3% compares to +20.4% for SPY (beat the market by 72.9%).
$10,000 invested 1 year ago→ $19,329 today
vs. S&P 500 (SPY) — same period beat market by 72.9%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($13.87)
✓Above 50-day MA ($17.12)
✓RSI(14) neutral zone (30–70) — currently 50.5
✓Positive return (+93.3%)
✓Within 10% of period high (−5.8%)
Period Range $18.15
$9.15$19.26
RSI (14) 50.5
0 · OversoldOverbought · 100
Key Metrics
Price$18.15
Period Return+93.3%
Period High$19.26
Period Low$9.15
Drawdown−5.8%
MA-50$17.12
MA-200$13.87
RSI (14)50.5
Avg Volume (30d)1.9M
vs. SPYbeat by 72.9%
Return Rank#164 of 1252
Trend Signals
Price is above the 200-day moving average ($13.87)